An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Exclusion Criteria

• •Treatment with systemic immunosuppressive/immunomodulating medication, immunoglobulin/blood products, or phototherapy within 4 weeks or 5 half-lives prior to randomization, whichever is longer.
• •Treatment with biologics within 5 half-lives (if known) or 16 weeks prior to randomization, whichever is longer.
• •Treatment with topical corticosteroid(s) (TCS), topical calcineurin inhibitor(s) (TCI), topical phosphodiesterase-4 (PDE-4) inhibitor, or other topical prescription treatments within 1 week prior to randomization.
• •Treatment with a live (attenuated) vaccine within 12 weeks prior to randomization.
• •Clinically significant active chronic or acute infection requiring systemic treatment within 4 weeks prior to randomization that may compromise the safety of the subject.
• •Skin infection within 1 week prior to the baseline visit.
• •Presence of hepatitis B or C infection at screening.
• •History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.
• •Participant has a positive or indeterminate test for tuberculosis at screening.
• •Participant is pregnant or lactating.